The condition
Understanding Fabry disease
A plain-English guide to what Fabry disease is, why it happens, how it's inherited, and what living with it can involve.
What causes it
Fabry disease is caused by changes (variants) in the GLA gene, which carries the instructions for an enzyme called alpha-galactosidase A. This enzyme's job is to break down a fatty substance called globotriaosylceramide, usually shortened to Gb3.
When the enzyme doesn't work properly, Gb3 isn't broken down and instead builds up inside cells throughout the body — especially in the cells lining blood vessels, and in the kidneys, heart and nervous system. Over years, this build-up progressively damages those organs, which is why Fabry disease is described as a progressive, multi-system condition.
It belongs to a wider family of around 70 rare inherited conditions known as lysosomal storage disorders — Fabry disease is one of the more common ones, alongside conditions such as Gaucher disease and the mucopolysaccharidoses (MPS).
How it's inherited
The GLA gene sits on the X chromosome, so Fabry disease follows an X-linked inheritance pattern.
Men (XY)
Have only one X chromosome. If it carries a GLA variant, they will have little or no working enzyme and typically develop symptoms.
Women (XX)
Have two X chromosomes. One working copy can often compensate to some degree, but many women still develop significant symptoms — historically under-recognised, this is now well understood.
Family patterns
A father with Fabry disease passes the variant to all of his daughters and none of his sons. A mother with Fabry disease has a 50% chance of passing it to each child, of either sex.
Because of this inheritance pattern, a new diagnosis often leads to genetic counselling and testing offered to other family members, even if they have no symptoms yet.
Classic vs late-onset Fabry disease
Beyond sex, one of the biggest factors shaping how Fabry disease presents is which broad type someone has — largely determined by how much working enzyme their particular GLA variant leaves them with.
Classic Fabry disease
Associated with very low or absent enzyme activity (typically under 1%). Usually begins in childhood or adolescence with the fuller symptom picture — pain crises, angiokeratomas (small dark skin spots), reduced sweating, and characteristic corneal changes — before progressing to affect the kidneys, heart and nervous system over time.
Late-onset (non-classic) Fabry disease
Associated with some residual enzyme activity, which usually means a milder course that emerges later — often in adulthood — and can be limited to a single organ system, most commonly the heart ("cardiac variant") or kidneys ("renal variant"), frequently without the earlier pain or skin symptoms seen in classic disease.
Late-onset Fabry disease is easy to miss, since it can look like unexplained heart or kidney disease rather than a "typical" Fabry presentation. It's often picked up through family testing after a relative's diagnosis, or through screening programmes for people with unexplained left ventricular hypertrophy, kidney failure, or a young stroke. Women can have either a classic or late-onset pattern, regardless of which type runs in their family, due to how the two X chromosomes are randomly switched on and off in different cells.
Signs and symptoms
Symptoms vary enormously between individuals — in type, severity and age of onset — which is part of why Fabry disease can take years to diagnose. Not everyone experiences all of these.
-
Childhood & adolescence
Burning or tingling pain in the hands and feet (acroparesthesia), often triggered by heat, exercise or fever; reduced sweating; heat and cold intolerance; abdominal pain and digestive symptoms; small, dark red skin spots (angiokeratomas); characteristic corneal changes seen only on eye examination.
-
Adulthood
Progressive kidney disease; thickening of the heart muscle, abnormal heart rhythms and increased risk of heart attack; increased risk of stroke; hearing loss or tinnitus; ongoing pain and fatigue.
-
Wellbeing
Living with chronic pain and an unpredictable, rare condition can affect mental health, education, work and relationships — this is a recognised part of the condition, not a separate issue, and support for it matters just as much as physical treatment.
See a fuller breakdown of symptoms — including mental health, joint pain and stroke risk →
Diagnosis
Enzyme assay
A blood test measuring alpha-galactosidase A activity. This is usually reliable in men but can be normal in some women who are still affected, so it isn't used alone.
Genetic testing
Identifies the specific GLA variant. This confirms diagnosis in women and men, and allows relatives to be tested for the same specific change.
Biomarkers
Blood or urine levels of Gb3 and related substances (such as lyso-Gb3) can support diagnosis and help monitor disease activity over time.
Organ assessment
Kidney function tests, heart scans (echocardiogram, MRI) and neurological review help establish how the condition is affecting the body and guide treatment decisions.
Treatment approaches
There's no cure for Fabry disease, but disease-specific treatments can slow or stabilise progression, alongside management of individual symptoms and regular organ monitoring. In the UK, these are prescribed and monitored through the specialist NHS centres — see Treatment Centres.
Enzyme replacement therapy (ERT)
Regular intravenous infusions of a lab-made version of the missing enzyme, typically given every two weeks, usually at a hospital or via homecare once established.
Oral chaperone therapy
A tablet-based treatment that stabilises a person's own enzyme so it works more effectively — an option for people with certain GLA variants confirmed as "amenable" by a specific lab test.
Symptom & organ management
Pain management, blood pressure and kidney-protective medication, cardiology follow-up, and lifestyle adjustments (such as avoiding known triggers for pain crises) all form part of routine care.
Newer & emerging therapies
Substrate reduction therapy and other approaches are in use or development. Your specialist team can advise which options, including clinical trials, may be relevant to you.
Treatment decisions are individual and depend on your genetic variant, symptoms and organ involvement. This page is a general guide — your specialist metabolic team is the right source for advice on your own care.